These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1797 related items for PubMed ID: 17538086

  • 1. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial.
    N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.
    J Clin Oncol; 2007 Sep 01; 25(25):3958-64. PubMed ID: 17761980
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec 01; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 4. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ, Hsu A.
    Clin J Oncol Nurs; 2008 Aug 01; 12(4):639-46. PubMed ID: 18676330
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B.
    J Clin Oncol; 2014 Mar 10; 32(8):752-9. PubMed ID: 24297945
    [Abstract] [Full Text] [Related]

  • 6. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec 10; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 7. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B.
    J Clin Oncol; 2009 Aug 10; 27(23):3822-9. PubMed ID: 19581539
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.
    J Clin Oncol; 2004 Mar 01; 22(5):909-18. PubMed ID: 14990647
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J, Subcutaneous Administration Propeukin Program Cooperative Group.
    J Clin Oncol; 2003 Nov 01; 21(21):3987-94. PubMed ID: 14581421
    [Abstract] [Full Text] [Related]

  • 10. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ, George DJ, Halabi S.
    J Clin Oncol; 2012 Sep 20; 30(27):3402-7. PubMed ID: 22891270
    [Abstract] [Full Text] [Related]

  • 11. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B, Brion N.
    Anticancer Res; 2011 Jan 20; 31(1):331-3. PubMed ID: 21273619
    [Abstract] [Full Text] [Related]

  • 12. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G.
    N Engl J Med; 2007 Sep 06; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract] [Full Text] [Related]

  • 13. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
    Alemao E, Rajagopalan S, Yang S, Curiel RE, Purvis J, Al MJ.
    J Med Econ; 2011 Sep 06; 14(2):245-52. PubMed ID: 21417551
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 06; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M.
    Acta Oncol; 2012 Jan 06; 51(1):101-6. PubMed ID: 21736504
    [Abstract] [Full Text] [Related]

  • 16. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B.
    Lancet Oncol; 2011 Jul 06; 12(7):673-80. PubMed ID: 21664867
    [Abstract] [Full Text] [Related]

  • 17. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep 06; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract] [Full Text] [Related]

  • 18. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA.
    Eur J Cancer; 2012 Feb 06; 48(3):333-9. PubMed ID: 22209391
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators.
    Lancet; 2007 Dec 22; 370(9605):2103-11. PubMed ID: 18156031
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Urol Oncol; 2009 Dec 22; 27(6):598-603. PubMed ID: 18818106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.